Model Integration and Configuration for siRNA Nucleic Acid

Data Characteristics

siRNA nucleic acid drug clinical trial data is highly specialized and structured. Data sources include global clinical trial registries (e.g., ClinicalTrials.gov, WHO ICTRP), pharmaceutical company internal trial reports, academic journals, and patent databases. Update frequency typically aligns with trial progress, with interim reports released quarterly or semi-annually, and final results published upon trial completion. Document structures generally follow ICH GCP (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice) guidelines. These include trial protocols, informed consent forms, CRF (Case Report Form) data, safety reports, and statistical analysis reports. Fields cover target genes, siRNA sequences, administration routes, dosages, subject characteristics (genotype, disease stage), biomarkers, pharmacokinetic/pharmacodynamic parameters (e.g., plasma concentration, gene silencing efficiency), and adverse events. Units typically use international standard measures such as mg/kg, nM, % inhibition, or specific disease scores.

Constraints Imposed by Data Characteristics on Model Integration and Configuration

The specialized and structured nature of siRNA nucleic acid drug data places strict demands on model integration. First, dispersed data sources and inconsistent update schedules require FastGPT's data connectors to support heterogeneous data integration, scheduled crawling, and incremental updates. This ensures data timeliness for model training and inference. Second, complex document structures, particularly PDF-formatted trial and statistical analysis reports, necessitate effective parsing of tables, charts, and nested text during data preprocessing to extract key fields. For example, siRNA sequences may appear as plain text or specific chemical structures, requiring specialized Named Entity Recognition (NER) and structured information extraction capabilities. Professional terminology for biomarkers, pharmacokinetic parameters, and adverse events also challenges the model's vocabulary and domain knowledge, requiring finer word embeddings and domain-adaptive training. Additionally, unit standardization requires strict validation during data cleaning to prevent misinterpretations due to inconsistent units.

Configuration Recommendations

Configuration Item	Recommended Value	Rationale
`maxContext`	`4000 characters`	Accommodates key paragraph lengths in trial protocols; ensures information completeness.
`Chunk size` (Chunk Length)	`500 characters`	Balances efficiency for long documents with semantic coherence.
`Recall count` (Recall Count)	`top 8`	Covers various relevant biomarkers and pharmacodynamic data.
`Similarity threshold` (Similarity Threshold)	`0.75`	Ensures recalled results are highly relevant to siRNA targets and indications.
`Rerank result count` (Rerank Return Count)	`top 3`	Highlights the most relevant clinical trial and safety data.
`PARSE_FILE_TIMEOUT_SECONDS`	`600 seconds`	Addresses complex parsing requirements for large PDF trial reports.

Common Pitfalls

When processing English siRNA sequences and target gene names, the model output often includes Chinese. This typically occurs because the base model's training corpus is biased towards Chinese and has not undergone sufficient domain-adaptive fine-tuning.
After deploying FastGPT in an intranet environment, the OneAPI module repeatedly restarts and reports failed errors. This often indicates issues with Docker container internal network configuration or an inability to correctly address dependent services (e.g., databases, model services), leading to health check failures.
During workflow debugging, the model returns OPENAI_BASE_URL-related errors. This likely means the environment variable configuration points to an unreachable or incorrectly started local large model service, preventing FastGPT from establishing a connection.

How to Verify Configuration

Upload a PDF trial report containing siRNA sequences, target genes, and key clinical indicators. Check the accuracy of knowledge base chunking and keyword extraction, especially for specialized terminology.
For a specific siRNA drug, ask questions about its clinical stage, primary indications, and adverse reactions. Observe if the model can accurately recall and integrate information from the knowledge base to answer.
Simulate a complex query, such as "Evaluate the efficacy and safety of siRNA targeting XX gene in YY disease, and list key biomarkers." Verify if the model can effectively rerank and summarize information from multiple recalled results.

The values given are common starting points and should be measured against the reader's own samples.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.